title: Phase II study of intravenous menogaril in patients with advanced breast cancer.
abstract: Menogaril was administered to 40 patients with advanced breast cancer who had not received anthracycline drugs previously. The drug was given iv as a 2-hour infusion, repeated every 4 weeks, at doses of 200 mg/m2 and 160 mg/m2 in good-risk and poor-risk patients. The overall response rate was 22% in patients with no prior chemotherapy and 10% in patients previously exposed to chemotherapy. Leukopenia was generally moderate and predictable. Phlebitis and erythema along the vein injected occurred in 34% and 17% of the cases, respectively. Menogaril is an active drug used in the treatment of patients with advanced breast cancer who have not had prior systemic therapy.
authors.affiliation: Division of Oncology, Ospedale San Giovanni, Switzerland.
authors.forename: C
authors.initials: C
authors.lastname: Sessa
authors.forename: S
authors.initials: S
authors.lastname: Gundersen
authors.forename: W
authors.initials: W
authors.lastname: ten Bokkel Huinink
authors.forename: J
authors.initials: J
authors.lastname: Renard
authors.forename: F
authors.initials: F
authors.lastname: Cavalli
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003630:Daunorubicin / Q000031:analogs & derivatives*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007970:Leukopenia / Q000139:chemically induced; D017290:Menogaril; D008875:Middle Aged; D009621:Nogalamycin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D012867:Skin / Q000187:drug effects; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D000970:Antineoplastic Agents; D017290:Menogaril; D009621:Nogalamycin; D003630:Daunorubicin